{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T15:40:07Z","timestamp":1754062807359,"version":"3.41.2"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"vor","delay-in-days":81,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.100912","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T04:04:44Z","timestamp":1742875484000},"page":"100912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Carfilzomib in relapsed\/refractory multiple myeloma patients \u2013 real world evidence \u2013 experiences of the Croatian cooperative group for hematologic diseases (KROHEM)"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5485-8529","authenticated-orcid":false,"given":"Davor","family":"Galusic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josip","family":"Batinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Krecak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5549-2150","authenticated-orcid":false,"given":"Barbara","family":"Dreta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delfa","family":"Radic Kristo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Pirsic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goran","family":"Rincic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasminka","family":"Sincic-Petricevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"Valkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9848-2225","authenticated-orcid":false,"given":"Milan","family":"Vujcic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marin","family":"Simunic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"Misura Jakobac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Sedinic Lacko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klara","family":"Brcic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlatka","family":"Perisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran","family":"Petricevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-4646","authenticated-orcid":false,"given":"Dragana","family":"Grohovac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hrvoje","family":"Holik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Moric Peric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Zekanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Bernes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luka","family":"Kuzat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilenia","family":"Romic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dubravka","family":"Zupanic Krmek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Basic-Kinda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2025.100912_bib0001","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2025.100912_bib0002","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100912_bib0003","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2025.100912_bib0004","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/leu.2016.390","article-title":"Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR","volume":"31","author":"Chng","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2025.100912_bib0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.ctarc.2025.100912_bib0006","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.3324\/haematol.2019.228684","article-title":"Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?","volume":"104","author":"Engelhardt","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ctarc.2025.100912_bib0007","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2025.100912_bib0008","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/17474086.2020.1729734","article-title":"Real-world outcomes and factors impacting treatment choice in relapsed and\/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd","volume":"13","author":"Chari","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.ctarc.2025.100912_bib0009","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/jha2.559","article-title":"Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database","volume":"3","author":"McCurdy","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.ctarc.2025.100912_bib0010","doi-asserted-by":"crossref","first-page":"8-17","DOI":"10.1016\/j.clml.2019.09.625","article-title":"Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark Randomized clinical trials of relapsed\/refractory multiple myeloma","volume":"20","author":"Chari","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"year":"2019","series-title":"Real-world Use of Carfilzomib Among Multiple Myeloma Patients with At Least One Prior Therapy","author":"Terpos","key":"10.1016\/j.ctarc.2025.100912_bib0011"},{"key":"10.1016\/j.ctarc.2025.100912_bib0012","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ctarc.2025.100912_bib0013","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1182\/blood-2018-99-113832","article-title":"Real world analysis of the incidence and impact of hypertension and cardiac toxicity associated with carfilzomib for patients with multiple myeloma","volume":"132","author":"Chavda","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2025.100912_bib0014","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2025.100912_bib0015","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00277-021-04407-0","article-title":"Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial","volume":"100","author":"Lee","year":"2021","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ctarc.2025.100912_bib0016","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/j.clml.2015.07.583","article-title":"Efficacy and safety of pre-approval carfilzomib-based therapy of multiple myeloma in daily practice \u2013 Experience from a German academic center","volume":"15","author":"Danhof","year":"2015","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"key":"10.1016\/j.ctarc.2025.100912_bib0017","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/ejh.13697","article-title":"Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed\/refractory multiple myeloma (RRMM)","volume":"107","author":"Pennipede","year":"2021","journal-title":"Eur. J. Haematol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T15:08:06Z","timestamp":1754060886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225000498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":17,"alternative-id":["S2468294225000498"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100912","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carfilzomib in relapsed\/refractory multiple myeloma patients \u2013 real world evidence \u2013 experiences of the Croatian cooperative group for hematologic diseases (KROHEM)","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100912"}}